Regorafenib 40 MG

DRUG3 trials

Sponsors

SC Liver Research Consortium, LLC, Sarcoma Alliance for Research through Collaboration, Zhongda Hospital

Conditions

Hepatocellular CarcinomaOsteosarcomaOsteosarcoma MetastaticOsteosarcoma RecurrentOsteosarcoma in Children

Phase 2

Optimization for Regorafenib in HCC

TerminatedNCT04476329

SC Liver Research Consortium, LLCHepatocellular Carcinoma

Start: 2021-01-21End: 2021-12-10Updated: 2021-12-30

SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

Active, not recruitingNCT04803877

Sarcoma Alliance for Research through CollaborationOsteosarcoma, Osteosarcoma in Children, Osteosarcoma Metastatic +1

Start: 2021-06-04End: 2026-06-30Target: 48Updated: 2025-10-31

Unknown Phase

A Real World Study of Regogfinib in HCC

Zhongda HospitalHepatocellular Carcinoma

Start: 2023-01-05End: 2023-12-31Target: 800Updated: 2022-12-29